Sanofi $SNY Stock Position Lifted by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its stake in Sanofi by 65.1%, acquiring an additional 127,534 shares, bringing their total holding to 323,582 shares valued at approximately $15.6 million.
• Analysts have become more favorable towards Sanofi, with notable upgrades from Deutsche Bank and Morgan Stanley, resulting in an average rating of "Buy" and a consensus target price of $62.67.
• For the latest quarter, Sanofi reported a net margin of 21.47% despite a revenue decline of 7.0% year-over-year, with earnings per share at $0.90 missing consensus estimates.

Aberdeen Group plc boosted its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 65.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 323,582 shares of the company's stock after purchasing an additional 127,534 shares during the period. Aberdeen Group plc's holdings in Sanofi were worth $15,632,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in SNY. Brighton Jones LLC grew its position in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after acquiring an additional 1,869 shares in the last quarter. Farther Finance Advisors LLC grew its position in Sanofi by 66.2% in the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after acquiring an additional 2,476 shares in the last quarter. GAMMA Investing LLC grew its position in Sanofi by 58.7% in the first quarter. GAMMA Investing LLC now owns 6,057 shares of the company's stock worth $336,000 after acquiring an additional 2,241 shares in the last quarter. Janney Montgomery Scott LLC grew its position in Sanofi by 3.6% in the first quarter. Janney Montgomery Scott LLC now owns 339,437 shares of the company's stock worth $18,825,000 after acquiring an additional 11,806 shares in the last quarter. Finally, Sowell Financial Services LLC bought a new stake in Sanofi in the first quarter worth approximately $328,000. 14.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on SNY shares. Weiss Ratings reissued a "hold (c)" rating on shares of Sanofi in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. Morgan Stanley upgraded shares of Sanofi from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $62.67.

Sanofi Price Performance

NASDAQ:SNY opened at $49.22 on Wednesday. The stock has a market cap of $120.86 billion, a P/E ratio of 11.83, a PEG ratio of 1.19 and a beta of 0.51. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a fifty day moving average price of $48.32 and a 200 day moving average price of $49.70. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.73 earnings per share. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.